Antiandrogens might help prevent or treat COVID-19 by blocking the virus's entry into cells.
4 citations
,
April 2020 in “medRxiv (Cold Spring Harbor Laboratory)” Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
April 2011 in “Reactions Weekly”
2 citations
,
April 2013 in “Expert Review of Endocrinology & Metabolism” Identifying nonclassic congenital adrenal hyperplasia and carriers of CYP21 mutations is challenging, and genetic counseling is recommended due to their prevalence.
January 2024 in “Circulation” Certain genetic mutations can lower bad cholesterol and reduce heart disease risk, leading to effective cholesterol-lowering drugs.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
1 citations
,
September 2022 in “TURKDERM” Systemic retinoids do not increase COVID-19 risk or severity.
49 citations
,
June 1998 in “Journal of Endocrinological Investigation” Cyproterone acetate plus ethinyl estradiol is generally more effective in treating hirsutism, but consider side effects and patient characteristics.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
28 citations
,
December 2001 in “European Journal of Pharmacology” M50054 may help treat hepatitis and hair loss from chemotherapy.
October 2025 in “International Journal of Risk & Safety in Medicine” Oral tofacitinib successfully treated a girl's severe skin and hair conditions.
69 citations
,
December 2015 in “Journal of Controlled Release” Nanocapsules can improve clobetasol delivery to hair follicles, reducing side effects.
1 citations
,
January 1995 in “Journal of Investigative Dermatology” RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.
508 citations
,
June 2009 in “Current drug metabolism” Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
June 2025 in “British Journal of Dermatology” JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.
24 citations
,
February 2007 in “Hormone and metabolic research” The substance MK386 effectively blocked testosterone conversion and reduced cell growth in certain skin cells, but inhibiting 5α-reductase alone may not greatly improve acne.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine may be effective for treating ashy dermatosis.
July 2024 in “Medical alphabet” JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.
10 citations
,
December 2002 in “International Journal of Dermatology” Cyproterone acetate can cause rare shortness of breath in women.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
May 2025 in “The Journal of Rheumatology” Anti-CD19 therapy may help treat SLE and NMOSD.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
2 citations
,
February 2024 in “Indian Dermatology Online Journal” Tofacitinib effectively improved hair regrowth and skin condition in a woman with alopecia totalis and lichen planus hypertrophicus.
9 citations
,
November 2012 in “Hepatology Research” A man lost all his hair permanently after hepatitis C treatment, a side effect not seen before.